Found: 273
Select item for more details and to access through your institution.
Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2299, doi. 10.1007/s13555-024-01247-4
- By:
- Publication type:
- Article
Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 16, p. 4608, doi. 10.3390/jcm13164608
- By:
- Publication type:
- Article
Use of Janus kinase inhibitors in atopic dermatitis – an update.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 3, p. 311, doi. 10.25259/IJDVL_14_2023
- By:
- Publication type:
- Article
Rapid progression of cutaneous T-cell lymphoma in a patient with erythroderma during dupilumab treatment, following prior sequential azathioprine, baricitinib and cyclosporine treatments.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 3, p. 353, doi. 10.25259/IJDVL_1090_2022
- By:
- Publication type:
- Article
Janus kinase inhibitors for alopecia areata: A narrative review.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2023, v. 89, n. 6, p. 799, doi. 10.25259/IJDVL_1093_2022
- By:
- Publication type:
- Article
A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia.
- Published in:
- Modern Rheumatology Case Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1093/mrcr/rxad012
- By:
- Publication type:
- Article
A case of extrapulmonary tuberculosis after use of baricitinib.
- Published in:
- Modern Rheumatology Case Reports, 2023, v. 7, n. 2, p. 364, doi. 10.1093/mrcr/rxac098
- By:
- Publication type:
- Article
Successful treatment of hip involvement in SAPHO syndrome with baricitinib.
- Published in:
- Rheumatology Advances in Practice, 2022, v. 6, n. 3, p. 1, doi. 10.1093/rap/rkac084
- By:
- Publication type:
- Article
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.
- Published in:
- Healthcare (2227-9032), 2021, v. 9, n. 11, p. 1575, doi. 10.3390/healthcare9111575
- By:
- Publication type:
- Article
P5‐47: Safety and efficacy of remdesivir, baricitinib and high‐dose steroid combination therapy in patients hospitalized with COVID‐19.
- Published in:
- Respirology, 2021, v. 26, p. 175, doi. 10.1111/resp.14150_254
- Publication type:
- Article
P5‐47: Safety and efficacy of remdesivir, baricitinib and high‐dose steroid combination therapy in patients hospitalized with COVID‐19.
- Published in:
- Respirology, 2021, v. 26, p. 175, doi. 10.1111/resp.14150_254
- Publication type:
- Article
Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 10, p. 1350, doi. 10.3390/cells12101350
- By:
- Publication type:
- Article
Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/ mTOR pathway via targeting JAK-STAT signaling of CD4<sup>+</sup> cells.
- Published in:
- Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1324892
- By:
- Publication type:
- Article
Circulating miRNA-19b as a biomarker of disease progression and treatment response to baricitinib in rheumatoid arthritis patients through miRNA profiling of monocytes.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.980247
- By:
- Publication type:
- Article
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1008392
- By:
- Publication type:
- Article
Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open‐label, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3064, doi. 10.1111/dom.15180
- By:
- Publication type:
- Article
A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis.
- Published in:
- Case Reports in Rheumatology, 2021, p. 1, doi. 10.1155/2021/8876847
- By:
- Publication type:
- Article
Successful treatment of alopecia areata‐associated trachyonychia with baricitinib.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 8, p. 1089, doi. 10.1111/ijd.17137
- By:
- Publication type:
- Article
Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 7, p. e130, doi. 10.1111/ijd.17198
- By:
- Publication type:
- Article
Real‐world experience of baricitinib in atopic dermatitis: including add‐on therapy for patients using dupilumab.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 2, p. 196, doi. 10.1111/ijd.16908
- By:
- Publication type:
- Article
Could baricitinib be a safe and effective therapeutic alternative for incoercible pruritus in patients with dermatitis herpetiformis?
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 1, p. e24, doi. 10.1111/ijd.16878
- By:
- Publication type:
- Article
Refractory livedoid vasculopathy successfully treated with baricitinib.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 11, p. e608, doi. 10.1111/ijd.16743
- By:
- Publication type:
- Article
Refractory livedoid vasculopathy successfully treated with baricitinib.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 9, p. 1204, doi. 10.1111/ijd.16467
- By:
- Publication type:
- Article
JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 8, p. 1088, doi. 10.1111/ijd.16676
- By:
- Publication type:
- Article
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib ‑ Revisiting the Immunomechanisms of the JAK Pathway.
- Published in:
- Indian Dermatology Online Journal, 2023, v. 14, n. 4, p. 465, doi. 10.4103/idoj.idoj_452_22
- By:
- Publication type:
- Article
Emerging role of baricitinib in dermatology practice: All we need to know!
- Published in:
- Indian Dermatology Online Journal, 2023, v. 14, n. 2, p. 153, doi. 10.4103/idoj.idoj_542_22
- By:
- Publication type:
- Article
Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID‐19.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 101, n. 3, p. 760, doi. 10.1111/cbdd.14179
- By:
- Publication type:
- Article
Use of baricitinib in treatment of COVID‐19: a systematic review.
- Published in:
- Medicinal Research Reviews, 2023, v. 43, n. 5, p. 1322, doi. 10.1002/med.21951
- By:
- Publication type:
- Article
Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability.
- Published in:
- Molecules, 2022, v. 27, n. 1, p. 168, doi. 10.3390/molecules27010168
- By:
- Publication type:
- Article
Solubility Data and Computational Modeling of Baricitinib in Various (DMSO + Water) Mixtures.
- Published in:
- Molecules, 2020, v. 25, n. 9, p. 2124, doi. 10.3390/molecules25092124
- By:
- Publication type:
- Article
A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats.
- Published in:
- Molecules, 2020, v. 25, n. 7, p. 1600, doi. 10.3390/molecules25071600
- By:
- Publication type:
- Article
Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 4, p. 647, doi. 10.1093/mr/roac089
- By:
- Publication type:
- Article
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
- Published in:
- Modern Rheumatology, 2018, v. 28, n. 4, p. 583, doi. 10.1080/14397595.2017.1392057
- By:
- Publication type:
- Article
Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
- Published in:
- Modern Rheumatology, 2018, v. 28, n. 1, p. 20, doi. 10.1080/14397595.2017.1307899
- By:
- Publication type:
- Article
Effectiveness of baricitinib in acquired reactive perforating collagenosis: a case report.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1388274
- By:
- Publication type:
- Article
Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1395288
- By:
- Publication type:
- Article
Efficacy and safety of baricitinib for the treatment of moderate‐to‐severe atopic dermatitis: A systematic review and meta‐analysis of randomized clinical trials.
- Published in:
- Clinical & Experimental Pharmacology & Physiology, 2022, v. 49, n. 11, p. 1139, doi. 10.1111/1440-1681.13704
- By:
- Publication type:
- Article
Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR THE DETERMINATION OF BARICITINIB AND ITS RELATED DRUG SUBSTANCES.
- Published in:
- Rasayan Journal of Chemistry, 2023, v. 16, n. 3, p. 1163, doi. 10.31788/RJC.2023.1638344
- By:
- Publication type:
- Article
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 3, p. 343, doi. 10.7326/M23-2593
- By:
- Publication type:
- Article
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
- Published in:
- PLoS ONE, 2022, v. 17, n. 8, p. 1, doi. 10.1371/journal.pone.0273340
- By:
- Publication type:
- Article
Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
- Published in:
- Inflammation, 2021, v. 44, n. 1, p. 206, doi. 10.1007/s10753-020-01322-w
- By:
- Publication type:
- Article
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 14, p. 7474, doi. 10.3390/ijms22147474
- By:
- Publication type:
- Article
Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 18, p. 6632, doi. 10.3390/ijms21186632
- By:
- Publication type:
- Article
Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
- Published in:
- Indian Journal of Pharmacology, 2022, v. 54, n. 3, p. 183, doi. 10.4103/ijp.ijp_1089_20
- By:
- Publication type:
- Article
Correlation between knowledge level, side effect severity, family support, and antiretroviral therapy adherence in HIV/AIDS patients in Greater Malang, East Java, Indonesia.
- Published in:
- Pharmacia (0428-0296), 2023, v. 70, n. 4, p. 1213, doi. 10.3897/pharmacia.70.e112645
- By:
- Publication type:
- Article
Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib.
- Published in:
- Pharmacia (0428-0296), 2023, v. 70, n. 4, p. 1177, doi. 10.3897/pharmacia.70.e112550
- By:
- Publication type:
- Article